Good MorningEquity markets were able to claw their way higher on Wednesday despite a hot read on inflation. The August CPI came in hotter than expected at the headline and core levels due to the rise of oil prices and threatens to push the Fed into another interest rate hike. The S&P 500 moved up less than 0.25% on the news, but the fact gains were made shows the market still does not believe inflation remains a problem.
The market seems to be heading into a bull trap. The S&P 500 is in rally mode despite the rising chance for additional interest rate hikes, and it is seriously mispricing the odds. As it is, the market has yet to price in another hike, and there could be more than 1 on the way. The price of WTI is up another 2.5% so far in September, the cause of hot inflation, and it is likely to continue rising. The next FOMC policy announcement is 1 week away and poses a significant threat to bullish traders. Featured: Elon’s BIGGEST warning yet? (Ad) 
|
Markets | | |
Are you a REIT investor looking for diversification in your passive income streams? REITs are terrific vehicles for gaining exposure to the real estate market without going through the hassle of purchasing property. They're also imperfect assets with certain risks. A REIT alternative can mitigate ... Read the Full Story |
|
From Our Partners | | Summer is almost Here! I would like to give you a special report that could help boost your portfolio this summer (and beyond).
It’s called 7 Best Stocks to Own in Summer 2025.
These are companies that not only thrive in the summer but are capable of generating juicy returns throughout the year.
To get it, just click the link below… but don’t dally, this is a limited-time offer. | | Get Your Copy of "7 Best Stocks to Own in Summer 2025" Here. |
|
Stocks | | |
With Tesla Inc (NASDAQ: TSLA) shares having already rallied close to 200% this year, many investors will understandably be wary about chasing the bid. It’s always nice to feel like you’re getting shares at a discount whenever you decide to buy, but unless you’re on... Read the Full Story |
|
Markets | | |
Kroger (NYSE: KR) is no exciting stock, but that is the point. Kroger isn’t an exciting stock, but it is a blue-chip player in consumer staples; it has solid revenue and earnings, sustainable cash flow, and pays a healthy dividend. To put its non-exciting quality into better perspective, Kro... Read the Full Story |
|
From Our Partners | | A little-known regulation quietly goes into effect this July.
And it's already being exploited by Wall Street and the Big Banks…
It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash.
Not stocks. Not real estate. And definitely not the U.S. dollar.
We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them. | | To help you get started, we're giving away a FREE Wealth Protection Guide that shows you exactly how |
|
Markets | | | Asian shares advanced Friday, with solid gains for Chinese markets after the central bank eased the reserve requirements for banks to encourage more lending and prop up the slowing economy.Hong Kong's Hang Seng surged 1.3% to 18,280.11 and the Shanghai Composite index was up 0.4%, at 3,138.94. Late ... Read the Full Story |
|
Markets | | |
Snacks and cleaning supplies aren’t the only thing on sale at Dollar General Corporation (NYSE:DG).
Last week, shares of the discount retailer fell to their lowest level since May 2019 following a dreadful second quarter earnings report. Like a bottle of generic bleach, the move erased all ... Read the Full Story |
|
From Our Partners | | 2025 is off to a turbulent start—markets are swinging wildly, inflation pressures remain high, and recession fears are creeping back into headlines.
But even in uncertain times, innovation doesn’t slow down.
In fact, artificial intelligence (AI) is accelerating faster than ever—creating new profit opportunities while the broader market struggles.
Our latest research reveals two AI stocks trading under $15 that could thrive even as volatility grows. These under-the-radar companies are positioned to ride the next wave of AI-driven demand—and they’re still flying below most investors’ radar. | | 👉[Click here to access your FREE AI stocks report now.] |
|
Markets | | |
Based out of Canada, Enbridge Inc. (NYSE: ENB) operates the world's longest crude oil and liquids transportation system, totaling 17,809 miles of active pipeline. While it also has core businesses in the natural gas pipelines, gas utilities and storage and renewable energy segment, it still collec... Read the Full Story |
|
Markets | | | The British economy shrank by 0.5% in July amid a series of strikes, particularly by doctors at the start of their careers, and unseasonably wet weather, official figures showed Wednesday.The Office for National Statistics said the strikes by so-called junior doctors weighed on health sector activit... Read the Full Story |
|
Markets | | | A record of more than one in five young Chinese are out of work, their career ambitions derailed by a depressed job market as the economy struggles to regain momentum after its long bout with COVID-19 Read the Full Story |
|
Markets | | | When the unexpected happens — whether fire, hail, or human error — renters insurance can provide much-needed stability. But many choose not to purchase coverage, including in places most frequently and hardest hit by natural disasters, new research shows.Linda Klamm, who works as an attorney for ins... Read the Full Story |
|
Markets | | | Shares of TKO Group, the new company that houses WWE and UFC, opened at $102 per share in their first day of trading on the New York Stock Exchange on Tuesday.Endeavor Group Holdings Inc. has closed its previously announced deal with World Wrestling Entertainment Inc. The pairing of WWE with the com... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey. | | View Today's Stock Pick |
|
